Market Access
There has been an increase in the number of settings in which outcomes research and Health Economic information have been critical to the development and commercialization of medical technologies. We pride ourselves on our record of supporting optimum price and best positioning within evidence-based clinical guidelines and Health Technology guidance. With the input of our HTA and Pricing and Reimbursement Advisory Boards our Market Access team has a unique insight into recent methodological developments and the evolution of local pricing and reimbursement policies.
Many restrictions currently affect our clients, with much of the motivation coming from the increasing cost of healthcare and the desire of governments to control the growth in healthcare spending and optimize resource allocation.
At Mapi Values, our approach to market access consists of a step-wise process to ensure that a product has every chance of getting to market and then becoming established. In short, this comprises:
- Planning outcomes and evidence generation strategies that optimize price, reimbursement and formulary access decisions
- Generating value messages and a value story by means of a thorough understanding of product profile, market awareness, evidence review, evidence synthesis, development and adaptation of Health Economic models
- Developing global value dossiers and country-specific reimbursement, pricing and HTA dossiers; preparing for reimbursement submissions and successful launch with value arguments tailored to the target audience
- Providing comprehensive post-launch market access support by using effectiveness evidence, economic data/models and value messaging to ensure continued market access
Now more than ever having the appropriate evidence to support market access is vitally important.
|
